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Inhalational or total intravenous anaesthesia: is total intravenous
anaesthesia useful and are there economic benefits?
J. Robert Sneyda and Katherine A. Holmesb
Introduction
In daily practice, clinicians typically choose drugs with
which they are familiar, tailoring anaesthetic techniques
toperceivedpatient benefit andpersonal preference rather
than economic benefit. Are these aims conflicting? Are
they even different? Making best use of finite resources
in the face of increasing demand is a priority given the
recession and public sector funding cuts in the UK and
changes in the structureofhealthcareprovision in theUSA.
The review explores the potential economic impact of
choice of general anaesthetic, comparing intravenous and
inhalational agents along the patient pathway from oper-
ating room to discharge and beyond. We have focused on
the contemporary general anaesthetics propofol, sevoflur-
ane, isoflurane and desflurane.
Aspects of economics
Consideration of economics and anaesthesia is not new.
Rowe [1], and Kettler and Crozier [2,3] have explored the
complexity and scope of the subject, and identified the
need to analyse costs with a global perspective to properly
assess cost-effectiveness. What does this imply? Differ-
ent types of economic analysis [1] applicable to health-
care are summarized in Table 1 [1]. The choice of
analysis depends on how benefits or outputs are to be
treated. A cost-identification analysis is an element of all
medical economic studies but can be seen as synonymous
with cost-minimization studies [4].
Costs can be described in a number of different ways
(Table 2) [1,5,6]. This can include total costs (fixed and
variable) and average costs (total cost divided by total
number of cases). Total costs can also be direct costs and
indirect costs. Health economists would refer to the latter
as those from loss of productivity [5].
Cost considerations
In the anaesthetic literature the approach to economic
comparison of total intravenous anaesthesia (TIVA) and
inhalational anaesthesia is often by their direct cost
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Purpose of review
The comparison of inhalational and intravenous anaesthesia has been the subject of
many controlled trials and meta-analyses. These reported diverse endpoints typically
including measures of the speed and quality of induction of anaesthesia, haemodynamic
changes, operating conditions, various measures of awakening, postoperative nausea
and vomiting and discharge from recovery and hospital as well as recovery of
psychomotor function. In a more patient-focused Health Service, measures with greater
credibility are overall patient satisfaction, time to return to work and long-term morbidity
and mortality. In practice, studies using easier to measure proxy endpoints dominate –
even though the limitations of such research are well known.
Recent findings
Recent study endpoints are more ambitious and include impact on survival from cancer
and the possibility of differential neurotoxic impact on the developing brain and
implications for neuro-behavioural performance.
Summary
Economic analysis of anaesthesia is complex and most published studies are naive,
focusing on drug acquisition costs and facility timings. Real health economics are much
more difficult. Preferred outcome measures would be whole institution costs or the
ability to reliably add an extra case to an operating list, close an operating room and
reduce the number of operating sessions offered or permanently decrease staffing.
Alongside this, however, potential long-term patient outcomes should be considered.
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[7–10]. There is disagreement regarding the regimen
with least drug cost, which may reflect differences in
caseload, the use of low-flow anaesthesia [10,11], variable
acquisition costs in different parts of the world [2] or
the expiry of patents. On average, the use of TIVA
gave higher drug costs [7,9,12–15], particularly if
wastage [16] or cost of consumables such as syringes
and pumps were included. This excess cost declined
with longer operations [17]. Many studies looked beyond
direct costs, assessing cost-effectiveness rather thanmini-
mization, recognizing that a cheaper anaesthetic that
results in postoperative pain or emesis may incur
additional costs and delay patient discharge [18]. Oppor-
tunities for savings in the operating room include time,
cost of other consumables and operating conditions,
which in turn may affect blood loss, surgical outcome
and length of stay. Cole et al. [19] report equal haemo-
dynamic stability with both inhalational and intravenous
anaesthesia for craniotomy but suggest propofol may
reduce intracranial pressure and increase cerebral
perfusion pressure. There was also no haemodynamic
difference found in septorhinoplasty patients, using remi-
fentanil in both groups [20].
In cardiac surgery volatile anaesthetics may be cardio-
protective [21]. However, Flier et al. [22] found no benefit
on cardiac morbidity and mortality or troponin concen-
trations after surgery. In general surgery, a faster recovery
of bowel function and earlier discharge was reported
when propofol was compared to desflurane for laparo-
scopic cholecystectomy [23].
Areas of economic impact in the recovery area or
postanaesthesia care unit (PACU) include length of
stay, costs, drug use and the ability to ‘step down’ to
a less intensive, and therefore less costly clinical
area.
The most common finding is that TIVA reduces the
incidence of postoperative nausea and vomiting, in the
early recovery period [23–27], and the decreased require-
ment for antiemetics may off-set a higher initial drug cost.
Further, patient dissatisfaction is often attributed to
nausea and vomiting – complications that both patients
and their anaesthetists wish to avoid [28,29] although
Fisher warns against the use of surrogate outcomes in this
regard [30].
Some studies report a faster or better quality recovery
with TIVA [8]; however, this seems to have little impact
on subsequent patient progress [31]. Other investigators
described faster recovery when inhalational agents were
used [16] but without difference in recovery of cognitive
function [25,32]. Some recent studies suggest increased
postoperative pain following isoflurane and sevoflurane
anaesthesia when compared to propofol [33,34] although
the suggestion that propofol has an analgesic effect has
been disputed [35] and the possibility of an antianalgesia
effect of residual volatile anaesthetic proposed instead.
Although anaesthetic drugs cost can vary between TIVA
and inhaled anaesthesia, any saving from cheaper drugs is
minimal compared to operating room or hospital episode
costs [36,37]. Despite this, although anaesthetic drug
costs are comparatively small they are, from a managerial
viewpoint, very visible [5,38].
Organizational issues
Any potential reduction in cost from faster and better
recovery from anaesthesia may be negated by a delay in
starting theatre cases, prolonged turnover time [39] and
downstream factors such as PACU staffing patterns.
Staffing is typically the greatest cost for a recovery area
and if a shorter recovery room stay does not result in the
reduction of staff hours or numbers then there is no real
economic saving [40,41]. Restructuring of PACU patient
inflow may have more impact; if patients are suitable to
either bypass PACU or be ‘fast-tracked’ to a nominated
area for faster discharge [42].
2 Ethics, economics and outcome
Key points
 There is increased scrutiny of all operating theatre
costs and drug budgets are easily targeted.
 Total intravenous anaesthesia appears to provide
decreased emesis and good recovery but often at
higher direct costs.
 Anaesthetic agents have been implicated as affect-
ing both long-term neurological development and
cancer recurrence and survival and further investi-
gative trials are underway.
 True health economics is complex and should
include all costs and benefits relating to the health-
care institution, the patient and society.
Table 1 Types of economic analysis applicable to anaesthesia
Input Output Output examples
Cost minimization
(cost identification)
Direct costs Not applicable Outcomes assumed equal
Cost-benefit All costs Economic benefits (benefits as monetary units) Money saved, production gains or return to work
Cost-effectiveness All costs Natural units (measured outcomes used directly) Numbers free from nausea, successfully treated cases
Cost-utility All costs Utility units (outcomes converted to common unit) Quality adjusted life years
Adapted from [1].
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Beyond hospital discharge
Current economic pressures make explicit the require-
ment that healthcare should be evidence-based and
delivered efficiently. Anaesthetists need to understand
the economics of anaesthesia care [43] as ‘medical
decision-making cannot be divorced from cost’ [44]. This
is a complex undertaking.
Potential economic benefits may be found along the
entire peri-operative track and beyond it. Improvements
in patient wellbeing after discharge may impact on return
to work, dependency and social functioning; however,
whilst these likely have economic impact to the patient,
improving them is unlikely to have financial benefits to
the healthcare provider. But benefits and costs can be
looked at from the different perspectives of the patient,
provider or society [4]. Commonly medical studies con-
sider patient benefits alone. So, what of the patient once
they are discharged? Few data describe anaesthetic drug
effects on patients’ experience after discharge. Endpoints
of interest would be the need to re-access healthcare
including visits to primary care or emergency department
attendance, perhaps re-admission.
Carvalho et al. [45] explored functional recovery during
the week following discharge after laparoscopic steriliza-
tion. Functional recovery was slow in both inhalational
and TIVA groups and not affected by anaesthetic tech-
nique [45]. Sung et al. [46] reported that patients anaes-
thetized with propofol group required less nursing care
and returned to work earlier those receiving isoflurane
during breast biopsy.
Neurological effects
True health economics considers the impact on society as
a whole and this takes us from ill-health to wellbeing.
Once our patients stop being patients, how long is it
before they return to their normal life? Do they return to
work or become a financial burden on the state? What is
their quality of life? Steinmetz et al. [47] reported that
elderly patients with cognitive dysfunction 1 week after
noncardiac surgery had increased dependency on social
transfer payments and increased likelihood of leaving the
workforce prematurely. Those in whom the cognitive
dysfunction persisted to 3 months experienced increased
mortality [47]. What we do not know is whether the type
of general anaesthetic used affected the risk of this
postoperative cognitive dysfunction; other risk factors
may be more important [48]. Recent investigations in
rats linked cognitive impairment to hippocampus pro-
inflammatory cytokine release precipitated by surgery
rather than anaesthesia [49] with greater effects in older
animals. Inhalational general anaesthesia can lead to
amyloid deposition as seen in Alzheimer’s disease
[50], but in animal studies isoflurane impacts negatively
on neonatal rats rather than adult ones, by reducing
neuro-genesis and causing memory deficit [51,52].
The impact of anaesthesia on long-tem outcomes is an
important contemporary research area and an enlarging
and concerning body of evidence. Anaesthesia, as whole,
is relatively well tolerated [53] and our drugs have a short
duration of effect with a generally reliable swift recovery.
Our impact on our patients is brief and beneficial. How
uncomfortable is it then, to consider the latest articles
looking at neurotoxicity from anaesthesia in children or
the differential risk of cancer metastasis dependent on
anaesthetic technique? Are we actually doing harm?
Emergence agitation in children after sevoflurane is well
known, appears short-lived [54] and was minimally
reduced by switching to propofol [55]. However, children
undergoing urological surgery before the age of 2 years
showed a trend towards an increased incidence of beha-
vioural disturbance [56] and children undergoing
multiple general anaesthetics before the age of 4 were
more likely to develop learning disabilities later [57]. It is
not clear if some anaesthetics are better tolerated than
others [58] and separating the long-term effects of the
condition necessitating surgery and the effects of the
procedure itself are problematic. In any case there are
times when the requirement for a general anaesthetic
cannot be avoided, hence further studies are needed [59]
and many are already underway [60].
Cancer outcomes
Of serious concern are the possible interactions of anaes-
thetic technique and cancer recurrence [61]. Surgery for
tumour removal is associated with the release of tumour
cells and the balance between the ability of these to seed
and the body’s immune defence determines the devel-
opment of clinical metastases [62]. The peri-operative
factors that can contribute to this process are surgery
which causes release of tumour cells and growth factors,
reduction of antiangiogenic factors and depression of the
cellular immune system, volatile anaesthesia-related
impairment of natural killer (NK) cells (amongst others)
and opioid-induced inhibition of both cellular and
humoral immunity [63,64].
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Table 2 Methods of describing costs in economic analysis
Direct costs Material and disposables used/wasted
Indirect costs Resulting from event, for example loss
of production
Fixed costs Remain the same, for example building rent
Variable costs Increases with case numbers, for example
drugs
Marginal costs Cost of one more/ fewer case
Intangible costs Nonphysical, for example goodwill
Adapted from [1] (originally adapted from [5,6]).
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Biki et al. [65] reported that patients undergoing radical
prostatectomy showed less biochemical cancer recur-
rence when a general anaesthetic was combined with
using an epidural in place of opioids. Similarly, the use of
paravertebral block to provide analgesia for breast cancer
surgery reduced the risk of tumour recurrence [66].
Gottschalk et al. [67] found epidural use gave no
decrease in cancer recurrence after colorectal surgery
but there was a potential benefit in older patients, who
may have had a different tumour type.
Regional anaesthesia might improve cancer outcomes
by reduction of surgical stress, decreasing need for
opioids (morphine promotes angiogenesis) and by allow-
ing the administration of lower amounts of volatile
anaesthetic. In contrast to volatile agents, propofol
attenuated the surgical stress response, not suppressing
NK cell activity or promoting lung tumour metastases
and in vitro inhibited breast tumour cell proliferation
[68,69].
The clinical trials so far have been retrospective and
descriptive but randomized trials are in progress [70].
Conclusion
Whilst in the past the use of total intravenous anaesthesia
has appeared to incur higher drug and equipment acqui-
sition cost, it has favourable effects such as reduced
postoperative nausea and vomiting and less immunosup-
pression in the perioperative period. Nevertheless with
only limited economic analysis of true outcome measures
and at present only retrospective evidence of potentially
improved cancer survival, as yet we do not have the
evidence to provide a definitive answer to a complex
question.
There is continuing development of novel anaesthetic
compounds [71] and these need to be evaluated for cost-
effectiveness and any effect on long-term outcomes.
Providing robust evidence will be the challenge. In
the meantime it is likely that a careful technique, tai-
lored to the individual patient’s needs, operation and
outcome is unlikely to have a drastic impact on institu-
tional spending but we should still do our part, however
small. If new evidence shows that our choice of anaes-
thetic has real impact on postoperative function or
patient survival then we will need to balance small-scale
economics with the bigger picture and first, do no
harm.
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